Jefferies Group LLC Blueprint Medicines Corp Transaction History

Jefferies Group LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$90.71 - $108.28 $1.27 Million - $1.52 Million	-14,000 Closed	0 $0
Q4 2020 Sep 21, 2023	BUY	$92.08 - $124.48 $1.29 Million - $1.74 Million	14,000 New	14,000 $1.57 Million
Q4 2020 Feb 16, 2021	BUY	$92.08 - $124.48 $248,708 - $336,220	2,701 Added 23.9%	14,000 $1.57 Million
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $1.64 Million - $2.27 Million	-28,644 Reduced 71.71%	11,299 $881,000
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $459,931 - $786,023	9,560 Added 31.46%	39,943 $2.34 Million
Q4 2019 Feb 13, 2020	BUY	$66.73 - $82.59 $332,982 - $412,124	4,990 Added 19.65%	30,383 $2.43 Million
Q3 2019 Nov 13, 2019	BUY	$72.9 - $101.41 $978,901 - $1.36 Million	13,428 Added 112.23%	25,393 $1.87 Million
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $879,906 - $1.17 Million	11,965 New	11,965 $1.13 Million
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $29,455 - $39,160	-500 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $30,480 - $50,590	500 New	500 $32,000

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.57B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.